ACTP: A webserver for predicting potential targets and relevant pathways of autophagy-modulating compounds
Metrics: PDF 401 views | HTML 396 views | ?
Tao Xie1,*, Lan Zhang1,*, Shouyue Zhang1,*, Liang Ouyang1, Haoyang Cai2, Bo Liu1
1State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, and Collaborative Innovation Center of Biotherapy, Chengdu 610041, China
2Center of Growth, Metabolism, and Aging, Key Laboratory of Bio-Resources and Eco-Environment, College of Life Sciences, Sichuan University, Chengdu 610064, China
*These authors contributed equally to this work
Bo Liu, e-mail: firstname.lastname@example.org
Keywords: autophagic compound-target prediction (ACTP), autophagy (macroautophagy), autophagy-activating compound, autophagy-inhibiting compound, webserver
Received: August 17, 2015 Accepted: January 13, 2016 Published: January 25, 2016
Autophagy (macroautophagy) is well known as an evolutionarily conserved lysosomal degradation process for long-lived proteins and damaged organelles. Recently, accumulating evidence has revealed a series of small-molecule compounds that may activate or inhibit autophagy for therapeutic potential on human diseases. However, targeting autophagy for drug discovery still remains in its infancy. In this study, we developed a webserver called Autophagic Compound-Target Prediction (ACTP) (http://actp.liu-lab.com/) that could predict autophagic targets and relevant pathways for a given compound. The flexible docking of submitted small-molecule compound (s) to potential autophagic targets could be performed by backend reverse docking. The webpage would return structure-based scores and relevant pathways for each predicted target. Thus, these results provide a basis for the rapid prediction of potential targets/pathways of possible autophagy-activating or autophagy-inhibiting compounds without labor-intensive experiments. Moreover, ACTP will be helpful to shed light on identifying more novel autophagy-activating or autophagy-inhibiting compounds for future therapeutic implications.
Primary Contact _
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.